Abstract
The way in which energy is used in cells is determined under the influence of environmental factors such as nutritional availability. Metabolic adaptation is mainly achieved through the modulation of metabolic gene expression, and may also involve epigenetic mechanisms that enable long-term regulation. Recent studies have identified that nutrients and their metabolites exert an important influence on the epigenome, as they serve as substrates and/or coenzymes for epigenetic-modifying enzymes. Some epigenetic factors have been shown to regulate metabolic genes leading to a shift in energy flow. These findings suggest the concept of metabolism–epigenome crosstalk that may contribute to the formation of a long-term metabolic phenotype. This is particularly relevant to the pathogenesis of obesity and associated metabolic disorders, in which pre- and post-natal nutritional conditions affect disease risks in adulthood. Moreover, most cancer cells exploit metabolic pathways for their hyperproliferative activity, while metabolic misregulation leads to aberrant epigenetic regulation in some cancers. This review explores the possible mechanisms of metabolism–epigenome crosstalk that may facilitate our understanding of physiology and diseases.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Mohyeldin, A., Garzon-Muvdi, T. & Quinones-Hinojosa, A. Oxygen in stem cell biology: a critical component of the stem cell niche. Cell Stem Cell 7, 150–161 (2010).
Desvergne, B., Michalik, L. & Wahli, W. Transcriptional regulation of metabolism. Physiol. Rev. 86, 465–514 (2006).
Kaochar, S. & Tu, B. P. Gatekeepers of chromatin: small metabolites elicit big changes in gene expression. Trends. Biochem. Sci. 37, 477–483 (2012).
Tseng, Y. H., Cypess, A. M. & Kahn, C. R. Cellular bioenergetics as a target for obesity therapy. Nat. Rev. Drug. Discov. 9, 465–482 (2010).
Ward, P. S. & Thompson, C. B. Metabolic reprogramming: a cancer hallmark even warburg did not anticipate. Cancer cell 21, 297–308 (2012).
Hanson, M. A. & Gluckman, P. D. Developmental origins of health and disease: new insights. Basic. Clin. Pharmacol. Toxicol. 102, 90–93 (2008).
Jimenez-Chillaron, J. C., Diaz, R., Martinez, D., Pentinat, T., Ramon-Krauel, M., Ribo, S. et al. The role of nutrition on epigenetic modifications and their implications on health. Biochimie 94, 2242–2263 (2012).
Suva, M. L., Riggi, N. & Bernstein, B. E. Epigenetic reprogramming in cancer. Science 339, 1567–1570 (2013).
Turcan, S., Rohle, D., Goenka, A., Walsh, L. A., Fang, F., Yilmaz, E. et al. IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 483, 479–483 (2012).
Xiao, M., Yang, H., Xu, W., Ma, S., Lin, H., Zhu, H. et al. Inhibition of alpha-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 26, 1326–1338 (2012).
Strahl, B. D. & Allis, C. D. The language of covalent histone modifications. Nature 403, 41–45 (2000).
Latchman, D. S. Gene control, (Garland Science, 2010).
Anderson, O. S., Sant, K. E. & Dolinoy, D. C. Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J. Nutr. Biochem. 23, 853–859 (2012).
Bernal, A. J. & Jirtle, R. L. Epigenomic disruption: the effects of early developmental exposures. Birth Defects Res. A Clin. Mol. Teratol. 88, 938–944 (2010).
Wolff, G. L., Kodell, R. L., Moore, S. R. & Cooney, C. A. Maternal epigenetics and methyl supplements affect agouti gene expression in Avy/a mice. Faseb J. 12, 949–957 (1998).
Pedersen, M. T. & Helin, K. Histone demethylases in development and disease. Trends. Cell. Biol. 20, 662–671 (2010).
Shi, Y., Lan, F., Matson, C., Mulligan, P., Whetstine, J. R., Cole, P. A. et al. Histone demethylation mediated by the nuclear amine oxidase homolog LSD1. Cell 119, 941–953 (2004).
Karytinos, A., Forneris, F., Profumo, A., Ciossani, G., Battaglioli, E., Binda, C. et al. A novel mammalian flavin-dependent histone demethylase. J. Biol. Chem. 284, 17775–17782 (2009).
Barile, M., Brizio, C., Valenti, D., De Virgilio, C. & Passarella, S. The riboflavin/FAD cycle in rat liver mitochondria. Eur. J. Biochem. 267, 4888–4900 (2000).
Tsukada, Y., Fang, J., Erdjument-Bromage, H., Warren, M. E., Borchers, C. H., Tempst, P. et al. Histone demethylation by a family of JmjC domain-containing proteins. Nature 439, 811–816 (2006).
Wu, H. & Zhang, Y. Mechanisms and functions of Tet protein-mediated 5-methylcytosine oxidation. Genes Dev. 25, 2436–2452 (2011).
Houtkooper, R. H., Pirinen, E. & Auwerx, J. Sirtuins as regulators of metabolism and healthspan. Nat. Rev. Mol. Cell. Biol. 13, 225–238 (2012).
Wellen, K. E., Hatzivassiliou, G., Sachdeva, U. M., Bui, T. V., Cross, J. R. & Thompson, C. B. ATP-citrate lyase links cellular metabolism to histone acetylation. Science 324, 1076–1080 (2009).
Mootha, V. K., Lindgren, C. M., Eriksson, K. F., Subramanian, A., Sihag, S., Lehar, J. et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat. Genet. 34, 267–273 (2003).
Patti, M. E., Butte, A. J., Crunkhorn, S., Cusi, K., Berria, R., Kashyap, S. et al. Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes: Potential role of PGC1 and NRF1. Proc. Natl Acad. Sci. USA 100, 8466–8471 (2003).
Kelley, D. E., He, J., Menshikova, E. V. & Ritov, V. B. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes 51, 2944–2950 (2002).
Hales, C. N. & Barker, D. J. Type 2 (non-insulin-dependent) diabetes mellitus: the thrifty phenotype hypothesis. Diabetologia 35, 595–601 (1992).
Gluckman, P. D., Hanson, M. A., Buklijas, T., Low, F. M. & Beedle, A. S. Epigenetic mechanisms that underpin metabolic and cardiovascular diseases. Nat. Rev. Endocrinol. 5, 401–408 (2009).
Turner, N. & Heilbronn, L. K. Is mitochondrial dysfunction a cause of insulin resistance? Trends Endocrinol. Metab. 19, 324–330 (2008).
Barres, R., Osler, M. E., Yan, J., Rune, A., Fritz, T., Caidahl, K. et al. Non-CpG methylation of the PGC-1alpha promoter through DNMT3B controls mitochondrial density. Cell. Metab. 10, 189–198 (2009).
Houten, S. M. & Auwerx, J. PGC-1alpha: turbocharging mitochondria. Cell 119, 5–7 (2004).
Brons, C., Jacobsen, S., Nilsson, E., Ronn, T., Jensen, C. B., Storgaard, H. et al. Deoxyribonucleic acid methylation and gene expression of PPARGC1A in human muscle is influenced by high-fat overfeeding in a birth-weight-dependent manner. J. Clin. Endocrinol. Metab. 95, 3048–3056 (2010).
Sanyal, A. J., Campbell-Sargent, C., Mirshahi, F., Rizzo, W. B., Contos, M. J., Sterling, R. K. et al. Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120, 1183–1192 (2001).
Sookoian, S., Rosselli, M. S., Gemma, C., Burgueno, A. L., Fernandez Gianotti, T., Castano, G. O. et al. Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor gamma coactivator 1alpha promoter. Hepatology 52, 1992–2000 (2010).
Mattson, M. P. Gene-diet interactions in brain aging and neurodegenerative disorders. Ann. Intern. Med. 139, 441–444 (2003).
Zheng, B., Liao, Z., Locascio, J. J., Lesniak, K. A., Roderick, S. S., Watt, M. L. et al. PGC-1alpha, a potential therapeutic target for early intervention in Parkinson’s disease. Sci. Transl. Med. 2, 52ra73 (2010).
Yao, J., Irwin, R. W., Zhao, L., Nilsen, J., Hamilton, R. T. & Brinton, R. D. Mitochondrial bioenergetic deficit precedes Alzheimer’s pathology in female mouse model of Alzheimer’s disease. Proc. Natl Acad. Sci. USA 106, 14670–14675 (2009).
Gesta, S., Tseng, Y. H. & Kahn, C. R. Developmental origin of fat: tracking obesity to its source. Cell 131, 242–256 (2007).
Yamauchi, T., Oike, Y., Kamon, J., Waki, H., Komeda, K., Tsuchida, A. et al. Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat. Genet. 30, 221–226 (2002).
Tateishi, K., Okada, Y., Kallin, E. M. & Zhang, Y. Role of Jhdm2a in regulating metabolic gene expression and obesity resistance. Nature 458, 757–761 (2009).
Inagaki, T., Tachibana, M., Magoori, K., Kudo, H., Tanaka, T., Okamura, M. et al. Obesity and metabolic syndrome in histone demethylase JHDM2a-deficient mice. Genes Cells 14, 991–1001 (2009).
Kamei, Y., Suganami, T., Ehara, T., Kanai, S., Hayashi, K., Yamamoto, Y. et al. Increased expression of DNA methyltransferase 3a in obese adipose tissue: studies with transgenic mice. Obesity (Silver Spring) 18, 314–321 (2010).
Ehara, T., Kamei, Y., Takahashi, M., Yuan, X., Kanai, S., Tamura, E. et al. Role of DNA methylation in the regulation of lipogenic glycerol-3-phosphate acyltransferase 1 gene expression in the mouse neonatal liver. Diabetes 61, 2442–2450 (2012).
Brasacchio, D., Okabe, J., Tikellis, C., Balcerczyk, A., George, P., Baker, E. K. et al. Hyperglycemia induces a dynamic cooperativity of histone methylase and demethylase enzymes associated with gene-activating epigenetic marks that coexist on the lysine tail. Diabetes 58, 1229–1236 (2009).
El-Osta, A., Brasacchio, D., Yao, D., Pocai, A., Jones, P. L., Roeder, R. G. et al. Transient high glucose causes persistent epigenetic changes and altered gene expression during subsequent normoglycemia. J. Exp. Med. 205, 2409–2417 (2008).
Hino, S., Sakamoto, A., Nagaoka, K., Anan, K., Wang, Y., Mimasu, S. et al. FAD-dependent lysine-specific demethylase-1 regulates cellular energy expenditure. Nat. Commun. 3, 758 (2012).
Wang, X. & Jin, H. The epigenetic basis of the Warburg effect. Epigenetics 5, 566–568 (2010).
Chen, M., Zhang, J., Li, N., Qian, Z., Zhu, M., Li, Q. et al. Promoter hypermethylation mediated downregulation of FBP1 in human hepatocellular carcinoma and colon cancer. PLoS One 6, e25564 (2011).
Sebastian, C., Zwaans, B. M., Silberman, D. M., Gymrek, M., Goren, A., Zhong, L. et al. The histone deacetylase SIRT6 is a tumor suppressor that controls cancer metabolism. Cell 151, 1185–1199 (2012).
Donohoe, D. R., Garge, N., Zhang, X., Sun, W., O’Connell, T. M., Bunger, M. K. et al. The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell. Metab. 13, 517–526 (2011).
Davie, J. R. Inhibition of histone deacetylase activity by butyrate. J. Nutr. 133, 2485S–2493S (2003).
Andriamihaja, M., Chaumontet, C., Tome, D. & Blachier, F. Butyrate metabolism in human colon carcinoma cells: implications concerning its growth-inhibitory effect. J. Cell. Physiol. 218, 58–65 (2009).
Lupton, J. R. Microbial degradation products influence colon cancer risk: the butyrate controversy. J. Nutr. 134, 479–482 (2004).
Donohoe, D. R., Collins, L. B., Wali, A., Bigler, R., Sun, W. & Bultman, S. J. The Warburg effect dictates the mechanism of butyrate-mediated histone acetylation and cell proliferation. Mol. Cell. 48, 612–626 (2012).
Ichimura, K. Molecular pathogenesis of IDH mutations in gliomas. Brain. Tumor. Pathol. 29, 131–139 (2012).
Rakheja, D., Konoplev, S., Medeiros, L. J. & Chen, W. IDH mutations in acute myeloid leukemia. Hum. Pathol. 43, 1541–1551 (2012).
Dang, L., White, D. W., Gross, S., Bennett, B. D., Bittinger, M. A., Driggers, E. M. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739–744 (2009).
Chowdhury, R., Yeoh, K. K., Tian, Y. M., Hillringhaus, L., Bagg, E. A., Rose, N. R. et al. The oncometabolite 2-hydroxyglutarate inhibits histone lysine demethylases. EMBO. Rep. 12, 463–469 (2011).
Xu, W., Yang, H., Liu, Y., Yang, Y., Wang, P., Kim, S. H. et al. Oncometabolite 2-hydroxyglutarate is a competitive inhibitor of alpha-ketoglutarate-dependent dioxygenases. Cancer cell 19, 17–30 (2011).
Figueroa, M. E., Abdel-Wahab, O., Lu, C., Ward, P. S., Patel, J., Shih, A. et al. Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. Cancer cell 18, 553–567 (2010).
Lian, C. G., Xu, Y., Ceol, C., Wu, F., Larson, A., Dresser, K. et al. Loss of 5-hydroxymethylcytosine is an epigenetic hallmark of melanoma. Cell 150, 1135–1146 (2012).
Losman, J. A., Looper, R. E., Koivunen, P., Lee, S., Schneider, R. K., McMahon, C. et al. (R)-2-hydroxyglutarate is sufficient to promote leukemogenesis and its effects are reversible. Science 339, 1621–1625 (2013).
Acknowledgements
SH is supported by a Grant-in-Aid for Scientific Research from Japan Society for the Promotion of Science, and by the Nakatomi Foundation. MN is supported by a Grant-in-Aid for Scientific Research on Innovative Areas (3307), from the Ministry of Education, Culture, Sports, Science and Technology of Japan, by the Japan Science and Technology Agency (CREST), and by a grant from the Takeda Science Foundation.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Hino, S., Nagaoka, K. & Nakao, M. Metabolism–epigenome crosstalk in physiology and diseases. J Hum Genet 58, 410–415 (2013). https://doi.org/10.1038/jhg.2013.57
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/jhg.2013.57
Keywords
This article is cited by
-
Rate of entropy model for irreversible processes in living systems
Scientific Reports (2017)
